<?xml version="1.0" encoding="utf-8"?>
<doi_batch xmlns="http://www.crossref.org/schema/4.3.6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" version="4.3.6" xsi:schemaLocation="http://www.crossref.org/schema/4.3.6 https://www.crossref.org/schemas/crossref4.3.6.xsd">
  <head>
    <doi_batch_id>_1630698759</doi_batch_id>
    <timestamp>1630698759</timestamp>
    <depositor>
      <depositor_name>brea</depositor_name>
      <email_address>akaviani@archbreastcancer.com</email_address>
    </depositor>
    <registrant>Farname Inc</registrant>
  </head>
  <body>
    <journal>
      <journal_metadata>
        <full_title>Archives of Breast Cancer</full_title>
        <abbrev_title>Arch Breast Cancer</abbrev_title>
        <issn media_type="electronic">2383-0433</issn>
      </journal_metadata>
      <journal_issue>
        <publication_date media_type="online">
          <month>04</month>
          <day>15</day>
          <year>2021</year>
        </publication_date>
      </journal_issue>
      <journal_article xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" publication_type="full_text" metadata_distribution_opts="any">
        <titles>
          <title>Breast Cancer Cell Lines, HER2/Neu Phenotype, and a Higher  Propensity to Reactive Oxygen Species Production</title>
        </titles>
        <contributors>
          <person_name contributor_role="author" sequence="first" language="en">
            <given_name>Zahra</given_name>
            <surname>Mohammadi Abgarmi</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Abbas</given_name>
            <surname>Sahebghadam Lotfi</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Saeid </given_name>
            <surname>Abroun</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Masoud</given_name>
            <surname>Soleimani</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Shahla</given_name>
            <surname>Mohammad Ganji</surname>
            <ORCID>https://orcid.org/0000-0003-2032-8209</ORCID>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Parvaneh</given_name>
            <surname>Baktash</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Arash</given_name>
            <surname>Moradi</surname>
            <ORCID>https://orcid.org/0000-0002-1038-084X</ORCID>
          </person_name>
        </contributors>
        <jats:abstract xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1">
          <jats:p>Background: The reactive oxygen species (ROS) generated in the biological systems play an important role in pathological conditions and specific normal cellular processes, such as signaling pathways and drug sensitivity. Methods: Intracellular ROS was determined using (2'-7'dichlorofluorescin diacetate) DCFH-DA fluorimetric probe, malondialdehyde as lipid peroxidation index detected by the Thiobarbituric acid reactive substances method. Cells' protein carbonyl contents were assessed with 2,4-Dinitrophenylhydrazine (DNPH) derivatization spectrophotometrically at 360-385 nm. Results: The oxidative stress induces ROS (p?0.05), MDA (Malondialdehyde) (p?0.05), and protein carbonylation (p?0.01) was significantly higher in HER2-positive BT-474, SK-BR-3, and MDA-MB-453 compared to the HER2-negative MDA-MB-231 and MCF-7 cell lines. Conclusion: We hypothesized that increased oxidative stress in HER2-positive cell lines is due to the oncogenic function of the HER2 and PI3K/Akt signaling activation, resulting in glycolysis induction. It is assumed that HER2-positive cell lines with high ROS levels are more vulnerable to further damage by increased ROS levels induced by pro-oxidant anticancer agents. </jats:p>
        </jats:abstract>
        <publication_date media_type="online">
          <month>04</month>
          <day>15</day>
          <year>2021</year>
        </publication_date>
        <pages>
          <first_page>137</first_page>
          <last_page>142</last_page>
        </pages>
        <ai:program xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" name="AccessIndicators">
          <ai:license_ref>http://creativecommons.org/licenses/by-nc/4.0</ai:license_ref>
        </ai:program>
        <doi_data>
          <doi>10.32768/abc.202182137-142</doi>
          <resource>https://www.archbreastcancer.com/index.php/abc/article/view/366</resource>
          <collection property="crawler-based">
            <item crawler="iParadigms">
              <resource>https://www.archbreastcancer.com/index.php/abc/article/download/366/484</resource>
            </item>
          </collection>
          <collection property="text-mining">
            <item>
              <resource mime_type="application/pdf">https://www.archbreastcancer.com/index.php/abc/article/download/366/484</resource>
            </item>
          </collection>
        </doi_data>
      </journal_article>
    </journal>
  </body>
</doi_batch>
